Anticancer vaccines have gained a new lease of life with techniques to personalise them to individual patients. Cutting edge developments in this re-energised field were revealed at the ESMO Immuno-Oncology Congress in Geneva, Switzerland.
The original anticancer vaccines, launched in the late 1990s, were based on shared tumour antigens and failed to induce a potent immune response. After decades of disappointing results, a number of advances have sparked a renewed interest in the field. These include new technologies and prediction algorithms to personalise vaccines, and the introduction of check point inhibitors for combination therapy
Dr Michal Bassani-Sternberg, Group Leader, Immunopeptidomics, Hi-TIDe Laboratory, Department of Oncology, University of Lausanne, Switzerland, and the Ludwig Institute for Cancer Research in Lausanne, said: “The ‘Modern anticancer vaccines’ session at the ESMO Immuno-Oncology Congress was timely since there is again a flurry of activity around anticancer vaccines. We can now customise vaccines for each patient based on the genomic information in their tumour, and the early results are promising.”
Personalisation has been made possible with high-throughput next generation sequencing. This technology identifies mutations that are unique to a patient’s tumour and are not found elsewhere in the body, meaning that a vaccine mounts a local immune response. Algorithms can predict which neoantigens should be targeted for vaccination.
Bassani-Sternberg said: “We have a good way to fish out and propose targets for vaccination. The first trials were published last year and showed that the selected targets were immunogenic, meaning that vaccination induced immune responses or amplified existing immune responses against these neoantigens. In addition, the vaccines worked well with check point inhibitors. We now need to see if vaccination against neoantigens leads to tumour regression.”
Neoantigens were explored in a dedicated session at the ESMO Immuno-Oncology Congress and were discussed in the session on modern anticancer vaccines, which also described the role of other vaccine targets. These include oncogenic proteins such as HER2, pathogens like the human papilloma virus (HPV), and prostate-specific antigens. These shared antigens are also being tested in combination with check point inhibitors.
Bassani-Sternberg said the combination of modern anticancer vaccines and check point inhibitors appears to generate the most effective immune response. “Vaccines can induce new responses in patients with ‘cold tumours’ which lack immune cells, thus making the environment receptive to check point inhibitors,” she said.
Numerous questions remain unanswered, such as when to vaccinate patients. Should this be immediately after surgery, when there are few tumour cells left, or beforehand? Should vaccines be administered against primary tumours and metastases? Will it be necessary to give new vaccines every few months as tumours evolve naturally and in response to treatment? How and when should vaccines be combined with other therapies?
But despite these questions, vaccination appears feasible. The technology to develop vaccines is available and getting better, the vaccines are safe and immunogenic, and there is openness from the regulators to testing vaccines in clinical trials. Bassani-Sternberg said: “We are counting on new technologies that have now matured. Next generation sequencing has made identification of vaccine targets more efficient, reliable, and cheaper. The algorithms to interpret this data are benchmarked and validated for predicting which targets are most likely to be immunogenic. Sequencing technologies are only going to get better and prediction tools will become even more accurate.”
“There is great hope for vaccines,” she continued. “And they have the potential to benefit most patients because almost all tumours have targets that could be vaccinated.”
Learn more: Anticancer Vaccines Gain new Lease of Life with Personalisation Techniques
The Latest on: Personalized anticancer vaccines
[google_news title=”” keyword=”Personalized anticancer vaccines” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Personalized anticancer vaccines
- UK Patients Testing World’s First Personalized mRNA Cancer Vaccine For Melanomaon April 26, 2024 at 1:26 pm
British patients are currently undergoing trials for a groundbreaking mRNA cancer vaccine tailored specifically for melanoma, with potential applications for lung, bladder, and kidney cancers as well.
- U.K. Tests World-First Personalized Skin Cancer Vaccineon April 26, 2024 at 9:08 am
Customized with genetic information from a patient’s own tumor, vaccines like this could one day be used against lung, kidney, bladder and colon cancer.
- ‘Real hope’ for cancer cure as personal mRNA vaccine for melanoma trialledon April 26, 2024 at 3:07 am
Excitement among patients and researchers as custom-built jabs enter phase 3 trial ...
- World’s first jab to stop skin cancer brings hope for patientson April 26, 2024 at 1:47 am
Dr Heather Shaw, national co-ordinating investigator, says the jab is being tested to see if it can work for lung, bladder and kidney cancer ...
- New drug which could 'cure cancer' tested on melanoma patient from Stevenageon April 25, 2024 at 8:40 pm
Steve Young, 52, from Stevenage, joined a clinical trial after being diagnosed with the potentially deadly form of skin cancer. | ITV News Anglia ...
- Man's 'bump on the head' was misdiagnosed FIVE times - and could have been fatalon April 25, 2024 at 8:37 pm
Steve Young, 52, was shocked to discover he had cancer after being misdiagnosed by a GP and dermatologists, none of whom thought he had anything serious ...
- British patients test world’s first personalised mRNA jab for melanomaon April 25, 2024 at 8:23 pm
The world’s first personalised mRNA cancer jab for melanoma – which also has the potential to stop lung, bladder and kidney cancer – is being tested in British patients. The “gamechanger” jab, which ...
- British patients test world’s first personalised MRNA cancer jab for melanomaon April 25, 2024 at 8:09 pm
The ‘gamechanger’ jab works by telling the body to hunt down cancer cells and prevent the deadly disease from coming back ...
- Music teacher’s ‘bump on the head’ turned out to be high-risk melanomaon April 25, 2024 at 4:03 pm
A music teacher whose “bump on the head” turned out to be potentially deadly melanoma is taking part in a groundbreaking clinical trial. Steve Young, 52, from Stevenage, was shocked to discover he had ...
- UK patients test personalised mRNA jab for melanomaon April 25, 2024 at 12:58 pm
UK health experts says a personalised mRNA cancer jab has the potential to cure people with melanoma and is being tested in other cancers.
via Bing News